Trio Medicines Limited (Trio) was established in 2006 by HMR and the late Sir James Black, the inventor of β-blockers and histamine H2 blockers, to develop a gastrin/CCK2 receptor antagonist, netazepide. Since then, Trio has grown and now has a pipeline of several potential new medicines at various phases of development from phase 1 to phase 3.

Trio Medicines is currently focused on producing effective treatments through the targeting of G-Protein Coupled Receptors (GPCRs) for a wide range of conditions. Our therapeutic expertise spans inflammatory, respiratory and cardiovascular conditions, as well as gastric neuroendocrine tumours, a designated orphan disease.

We have ongoing pre-clinical and clinical development programmes for netazepide, ceclazepide (a follow-up gastrin/CCK2 receptor antagonist), TR4 (a β2-adrenoceptor antagonist), and TR8 (a member of the annexin family).